Tel Aviv-based genetic testing company Identifai-Genetics has raised USD 3.3 million in a post-seed funding round led by eHealth Ventures and included participation from Dr. Ron Sabar, founder and CMO of Sabar Health, among others. The company claims to have raised over USD 6 million in equity investments and R&D grants. The planned uses of the funds were not disclosed.
Identifai Genetics is focused on developing a liquid biopsy test that uses maternal blood samples for the non-invasive detection of fetal genetic disorders at an early stage of pregnancy. The company claims to offer the only available clinical solution for an early, non-invasive prenatal genetic screening, from point mutations to chromosomal anomalies. By identifying severe genetic disorders with high accuracy, Identifai-Genetics aims to help mitigate the risk of amniocentesis and placental cysts. The company is planning to launch clinical studies to further validate its technology.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.